Skip to main content

Advertisement

SpringerLink
Log in

Chronic kidney disease and cardiovascular complications

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

Cardiovascular diseases such as coronary artery disease, congestive heart failure, arrhythmias and sudden cardiac death represent main causes of morbidity and mortality in patients with chronic kidney disease (CKD). Pathogenesis includes close linkage between heart and kidneys and involves traditional and non-traditional cardiovascular risk factors. According to a well-established classification of cardiorenal syndrome, cardiovascular involvement in CKD is known as “type-4 cardiorenal syndrome” (chronic renocardiac). The following review makes an overview about epidemiology, pathophysiology, diagnosis and treatment of cardiovascular complications in CKD patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Ronco C (2011) The cardiorenal syndrome: basis and common ground for a multidisciplinary patient-oriented therapy. Cardiorenal Med 1:3–4

  2. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J, ADHERE Scientific Advisory Committee and Investigators (2007) High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 13(6):422–430

    Article  PubMed  Google Scholar 

  3. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE (1995) The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 5(12):2024–2031

    CAS  PubMed  Google Scholar 

  4. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS (1995) Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 47(3):884–890

    Article  CAS  PubMed  Google Scholar 

  5. Selby NM, Kolhe NV, McIntyre CW et al (2012) Defining the cause of death in hospitalized patients with acute kidney injury. PLoS One 7(11):e48580

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Garg AX, Clark WF, Haynes RB, House AA (2002) Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int 61(4):1486–1494

    Article  PubMed  Google Scholar 

  7. US Renal Data System (2012) USRDS 2012 Annual data report: atlas of end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD

  8. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX (2006) Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 17(7):2034–2047

    Article  PubMed  Google Scholar 

  9. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351(13):1296–1305

    Article  CAS  PubMed  Google Scholar 

  10. US Renal Data System (2009) USRDS 2009 Annual data report: atlas of end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD

  11. Shastri S, Sarnak MJ (2010) Cardiovascular disease and CKD: core curriculum 2010. Am J Kidney Dis 56(2):399–417

    Article  PubMed  Google Scholar 

  12. Stevens LA, Li S, Wang C, Huang C, Becker BN, Bomback AS, Brown WW, Burrows NR, Jurkovitz CT, McFarlane SI, Norris KC, Shlipak M, Whaley-Connell AT, Chen SC, Bakris GL, McCullough PA (2010) Prevalence of CKD and comorbid illness in elderly patients in the united states: results from the kidney early evaluation program (KEEP). Am J Kidney Dis 55(3 Suppl 2):S23–S33

    Article  PubMed  Google Scholar 

  13. Bansal N, Keane M, Delafontaine P, Dries D, Foster E, Gadegbeku CA, Go AS, Hamm LL, Kusek JW, Ojo AO, Rahman M, Tao K, Wright JT, Xie D, Hsu CY, CRIC Study Investigators (2013) A longitudinal study of left ventricular function and structure from CKD to ESRD: the CRIC study. Clin J Am Soc Nephrol 8(3):355–362

    Article  PubMed Central  PubMed  Google Scholar 

  14. Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, Chambless LE, Coresh J (2007) Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 18(4):1307–1315

    Article  CAS  PubMed  Google Scholar 

  15. Waheed S, Matsushita K, Sang Y, Hoogeveen R, Ballantyne C, Coresh J, Astor BC (2012) Combined association of albuminuria and cystatin C-based estimated GFR with mortality, coronary heart disease, and heart failure outcomes: the atherosclerosis risk in communities (ARIC) study. Am J Kidney Dis 60(2):207–216

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Kober L, Squire IB, Swedberg K, Dobson J, Poppe KK, Whalley GA, Doughty RN (2013) Meta-analysis global group in chronic heart failure (MAGGIC). Predicting survival in heart failure: a risk score based on 39,372 patients from 30 studies. Eur Heart J 34(19):1404–1413

    Article  PubMed  Google Scholar 

  17. Levin A, Singer J, Thompson CR, Ross H, Lewis M (1996) Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 27(3):347–354

    Article  CAS  PubMed  Google Scholar 

  18. Parfrey PS, Harnett JD, Griffiths SM, Taylor R, Hand J, King A, Barre PE (1990) The clinical course of left ventricular hypertrophy in dialysis patients. Nephron 55(2):114–120

    Article  CAS  PubMed  Google Scholar 

  19. Lezaic V, Tirmenstajn-Jankovic B, Bukvic D, Vujisic B, Perovic M, Novakovic N, Dopsaj V, Maric I, Djukanovic L (2009) Efficacy of hyperphosphatemia control in the progression of chronic renal failure and the prevalence of cardiovascular calcification. Clin Nephrol 71(1):21–29

    Article  CAS  PubMed  Google Scholar 

  20. Di Lullo L, Floccari F, Santoboni A, Barbera V, Rivera RF, Granata A, Morrone L, Russo D (2013) Progression of cardiac valve calcification and decline of renal function in CKD patients. J Nephrol 26(4):739–744

    Article  PubMed  Google Scholar 

  21. Olgaard K, Lewin E, Silver J (2011) Calcimimetics, vitamin D and ADVANCE in the management of CKD–MBD. Nephrol Dial Transplant 26(4):1117–1119

  22. MacRae JM, Pandeya S, Humen DP, Krivitski N, Lindsay RM (2004) Arteriovenous fistula-associated high-output cardiac failure: a review of mechanisms. Am J Kidney Dis 43(5):e17–e22

    Article  PubMed  Google Scholar 

  23. Di Lullo L, Floccari F, Polito P (2011) Right ventricular diastolic function in dialysis patients could be affected by vascular access. Nephron Clin Pract 118:c258–c262

    Article  Google Scholar 

  24. Fort J (2005) Chronic renal failure: a cardiovascular risk factor. Kidney Int 68(Suppl 99):S25–S29

  25. Schiffrin EL, Lipman ML, Mann JF (2007) Chronic kidney disease: effects on the cardiovascular system. Circulation 116(1):85–97

    Article  PubMed  Google Scholar 

  26. Bologa RM, Levine DM, Parker TS et al (1998) Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 32(1):107–114

    Article  CAS  PubMed  Google Scholar 

  27. Parikh SV, de Lemos JA (2006) Biomarkers in cardiovascular disease: integrating pathophysiology into clinical practice. Am J Med Sci 332(4):186–197

    Article  PubMed  Google Scholar 

  28. Austin WJ, Bhalla V, Hernandez-Arce I et al (2006) Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. Am J Clin Pathol 126(4):506–512

    Article  CAS  PubMed  Google Scholar 

  29. Ronco C, Di Lullo L (2014) Cardiorenal syndrome. Heart Fail Clin 10(2):251–280

    Article  PubMed  Google Scholar 

  30. Maisel AS, Katz N, Hillege HL et al (2011) Biomarkers in kidney and heart disease. Nephrol Dial Transplant 26(1):62–74

    Article  PubMed  Google Scholar 

  31. Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32(5 Suppl 3):S112–S119

    Article  CAS  PubMed  Google Scholar 

  32. Ichikawa I, Pfeffer JM, Pfeffer MA, Hostetter TH, Brenner BM (1984) Role of angiotensin II in the altered renal function of congestive heart failure. Circ Res 55(5):669–675

    Article  CAS  PubMed  Google Scholar 

  33. Entin-Meer M, Ben-Shoshan J, Maysel-Auslender S, Levy R, Goryainov P, Schwartz I, Barshack I, Avivi C, Sharir R, Keren G (2012) Accelerated renal fibrosis in cardiorenal syndrome is associated with long-term increase in urine neutrophil gelatinase-associated lipocalin levels. Am J Nephrol 36(2):190–200

    Article  CAS  PubMed  Google Scholar 

  34. Lekawanvijit S, Kompa AR, Zhang Y, Wang BH, Kelly DJ, Krum H (2012) Myocardial infarction impairs renal function, induces renal interstitial fibrosis, and increases renal KIM-1 expression: implications for cardiorenal syndrome. Am J Physiol Heart Circ Physiol 302(9):H1884–H1893

    Article  CAS  PubMed  Google Scholar 

  35. Jovanovich A, Ix JH, Gottdiener J, McFann K, Katz R, Kestenbaum B, de Boer IH, Sarnak M, Shlipak MG, Mukamal KJ, Siscovick D, Chonchol M (2013) Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults. Atherosclerosis 231(1):114–119

    Article  CAS  PubMed  Google Scholar 

  36. Shamseddin MK, Parfrey PS, Medscape (2011) Sudden cardiac death in chronic kidney disease: epidemiology and prevention. Nat Rev Nephrol 7(3):145–154

  37. Kajstura J, Cigola E, Malhotra A et al (1997) Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol 29(3):859–870

    Article  CAS  PubMed  Google Scholar 

  38. Kingma JG Jr, Vincent C, Rouleau JR, Kingma I (2006) Influence of acute renal failure on coronary vasoregulation in dogs. J Am Soc Nephrol 17(5):1316–1324

    Article  CAS  PubMed  Google Scholar 

  39. Lok DJ, Lok SI, Bruggink-André de la Porte PW, Badings E, Lipsic E, van Wijngaarden J, de Boer RA, van Veldhuisen DJ, van der Meer P (2013) Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol 102(2):103–110

    Article  CAS  PubMed  Google Scholar 

  40. Chan CT, Levin NW, Chertow GM et al (2010) Determinants of cardiac autonomic dysfunction in ESRD. Clin J Am Soc Nephrol 5(10):1821–1827

    Article  PubMed Central  PubMed  Google Scholar 

  41. Winkelmayer WC, Patrick AR, Liu J et al (2011) The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol 22(2):349–357

    Article  PubMed Central  PubMed  Google Scholar 

  42. Baber U, Howard VJ, Halperin JL et al (2011) Association of chronic kidney disease with atrial fibrillation among adults in the United States: reasons for geographic and racial differences in stroke (REGARDS) study. Circ Arrhythm Electrophysiol 4(1):26–32

    Article  PubMed Central  PubMed  Google Scholar 

  43. Soliman EZ, Prineas RJ, Go AS et al (2010) Chronic kidney disease and prevalent atrial fibrillation: the chronic renal insufficiency cohort (CRIC). Am Heart J 159(6):1102–1107

    Article  PubMed Central  PubMed  Google Scholar 

  44. Boerrigter G, Costello-Boerrigter LC, Abraham WT, Sutton MG, Heublein DM, Kruger KM, Hill MR, McCullough PA, Burnett JC Jr (2008) Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate. J Card Fail 14(7):539–546

    Article  PubMed Central  PubMed  Google Scholar 

  45. Cai Q, Mukku VK, Ahmad M (2013) Coronary artery disease in patients with chronic kidney disease: a clinical update. Curr Cardiol Rev 9(4):331–339

    Article  PubMed Central  PubMed  Google Scholar 

  46. Wang LW, Fahim MA, Hayen A, Mitchell RL, Lord SW, Baines LA, Craig JC, Webster AC (2011) Cardiac testing for coronary artery disease in potential kidney transplant recipients: a systematic review of test accuracy studies. Am J Kidney Dis 57(3):476–487

    Article  PubMed  Google Scholar 

  47. Chonchol M, Whittle J, Desbien A, Orner MB, Petersen LA, Kressin NR (2008) Chronic kidney disease is associated with angiographic coronary artery disease. Am J Nephrol 28(2):354–360

    Article  PubMed  Google Scholar 

  48. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD (2003) Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 63(3):793–808

    Article  PubMed  Google Scholar 

  49. Cheung AK, Sarnak MJ, Yan G et al (2000) Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58(1):353–362

    Article  CAS  PubMed  Google Scholar 

  50. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z (2008) Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces it into the uremic puzzle? Clin J Am Soc Nephrol 3(2):505–521

    Article  CAS  PubMed  Google Scholar 

  51. Moe SM, Chen NX (2008) Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 19(2):213–216

    Article  CAS  PubMed  Google Scholar 

  52. Shioi A, Taniwaki H, Jono S et al (2001) Monckeberg’s medial sclerosis and inorganic phosphate in uremia. Am J Kidney Dis 38(supplement 1):S7–S9

  53. Shanahan CM, Cary NRB, Salisbury JR, Proudfoot D, Weissberg PL, Edmonds ME (1999) Medial localization of mineralization-regulating proteins in association with Monckeberg’s sclerosis: evidence for smooth muscle cell-mediated vascular calcification. Circulation 100(21):2168–2176

    Article  CAS  PubMed  Google Scholar 

  54. Stenvinkel P, Chung SH, Heimbürger O, Lindholm B (2001) Malnutrition, inflammation, and atherosclerosis in peritoneal dialysis patients. Perit Dial Int 21(supplement 3):S157–S162

  55. London GM, Guerin AP, Marchais SJ, Metivier, Pannier FB, Adda H (2003) Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18(9):1731–1740

  56. Caliskan Y, Demirturk M, Ozkok A et al (2010) Coronary artery calcification and coronary low velocity in haemodialysis patients. Nephrol Dial Transplant 25(8):2685–2690

    Article  CAS  PubMed  Google Scholar 

  57. Van Der Velde M, Matsushita K, Coresh J et al (2011) Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality: a collaborative meta-analysis of high-risk population cohorts. Kidney Int 79(12):1341–1352

  58. Shirani J, Berezowski K, Roberts WC (1995) Quantitative measurement of normal and excessive (cor adiposum) subepicardial adipose tissue, its clinical significance, and its effect on electrocardiographic QRS voltage. Am J Cardiol 76(5):1–19

    Article  Google Scholar 

  59. Di Lullo L, Floccari F, Granata A, D’Amelio A, Rivera R, Fiorini F, Malaguti M, Timio M (2011) Ultrasonography: Ariadne’s thread in the diagnosis of cardiorenal syndrome. Cardiorenal Med 2(1):11–17

  60. Di Lullo L, Floccari F, Rivera R, Barbera V, Granata A, Otranto G, Mudoni A, Malaguti M, Santoboni A, Ronco C (2013) Pulmonary hypertension and right heart failure in chronic kidney disease: new challenge for 21st-century cardionephrologists. Cardiorenal Med 3:96–103

  61. Edwards NC, Moody WE, Chue CD, Ferro CJ, Townend JN, Steeds RP (2014) Defining the natural history of uremic cardiomyopathy in chronic kidney disease: the role of cardiovascular magnetic resonance. JACC Cardiovasc Image 7(7):703–714

  62. Stewart GA, Foster J, Cowan M et al (1999) Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging. Kidney Int 56:2248–2253

    Article  CAS  PubMed  Google Scholar 

  63. Silberberg JS, Barre PE, Prichard SS, Sniderman AD (1989) Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36:286–290

    Article  CAS  PubMed  Google Scholar 

  64. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE (1996) Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 11:1277–1285

    Article  CAS  PubMed  Google Scholar 

  65. Ritz E, Bommer J (2009) Cardiovascular problems on hemodialysis: current deficits and potential improvement. Clin J Am Soc Nephrol 4:S71–S78

    Article  PubMed  Google Scholar 

  66. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ (2005) Recommendations for chamber quantification: a report from the American society of echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European association of echocardiography, a branch of the European society of cardiology. J Am Soc Echocardiogr 18:1440–1463

    Article  PubMed  Google Scholar 

  67. Takeuchi M, Nishikage T, Mor-Avi V, Sugeng L, Weinert L, Nakai H, Salgo IS, Gerard O, Lang RM (2008) Measurement of left ventricular mass by real-time three-dimensional echocardiography: validation against magnetic resonance and comparison with two-dimensional and m-mode measurements. J Am Soc Echocardiogr 21:1001–1005

    Article  PubMed  Google Scholar 

  68. Pewsner D, Juni P, Egger M, Battaglia M, Sundstrom J, Bachmann LM (2007) Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. BMJ 335:711

    Article  PubMed Central  PubMed  Google Scholar 

  69. Kribben A, Witzke O, Hillen U, Barkhausen J, Daul AE, Erbel R (2009) Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. J Am Coll Cardiol 53:1621–1628

    Article  CAS  PubMed  Google Scholar 

  70. Karohl C, D’Marco Gascón L, Raggi P (2011) Noninvasive imaging for assessment of calcification in chronic kidney disease. Nat Rev Nephrol 7(10):567–577

    Article  CAS  PubMed  Google Scholar 

  71. Desbien AM, Chonchol M, Gnahn H, Sander D (2008) Kidney function and progression of carotid intima-media thickness in a community study Am J Kidney Dis 51(4):584–593

  72. Salk I, Yildiz G, Egilmez H, Atalar MH, Candan F, Cetin A (2014) Carotid artery Doppler ultrasonography in patients with chronic kidney disease. Med Sci Monit 7(20):11–17

    Google Scholar 

  73. Briet M, Bozec E, Laurent S et al (2006) Arterial stiffness and enlargement in mild-to-moderate chronic kidney disease. Kidney Int 69:350–357

    Article  CAS  PubMed  Google Scholar 

  74. Chue CD, Edwards NC, Ferro CJ, Townend JN, Steeds RP (2013) Effects of age and chronic kidney disease on regional aortic distensibility: a cardiovascular magnetic resonance study. Int J Cardiol 168:4249–4254

    Article  PubMed  Google Scholar 

  75. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345(12):861–869

    Article  CAS  PubMed  Google Scholar 

  76. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345(12):851–860

    Article  CAS  PubMed  Google Scholar 

  77. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ, Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group (2003) Cardiovascular outcomes in the irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 138(7):542–549

    Article  CAS  PubMed  Google Scholar 

  78. Zannad F, Kessler M, Lehert P, Grunfeld JP, Thuilliez C, Leizorovicz A, Lechat P (2006) Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 70(7):1318–1324

    Article  CAS  PubMed  Google Scholar 

  79. Lesogor A, Cohn JN, Latini R, Tognoni G, Krum H, Massie B, Zalewski A, Kandra A, Hua TA, Gimpelewicz C (2013) Interaction between baseline and early worsening of renal function and efficacy of renin–angiotensin–aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study. Eur J Heart Fail 15(11):1236–1244

    Article  CAS  PubMed  Google Scholar 

  80. Cice G, Ferrara L, D’Andrea A, D’Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabro R (2003) Carvedilol increases 2-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 41(9):1438–1444

    Article  CAS  PubMed  Google Scholar 

  81. Cohen-Solal A, Kotecha D, van Veldhuisen DJ, Babalis D, Bohm M, Coats AJ, Roughton M, Poole-Wilson P, Tavazzi L, Flather M, SENIORS Investigators (2009) Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. Eur J Heart Fail 11(9):872–880

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  82. The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative north scandinavian enalapril survival study (CONSENSUS). N Engl J Med 316(23):1429–1435

  83. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK (2007) Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72(9):1130–1137

  84. EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS (2012) Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367(26):2482–2494

  85. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK, TNT (Treating to New Targets) Investigators (2008) Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (treating to new targets) study. J Am Coll Cardiol 51(15):1448–1454

    Article  CAS  PubMed  Google Scholar 

  86. Wanner C, Krane V, Marz W et al (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353(3):238–248

    Article  CAS  PubMed  Google Scholar 

  87. Fellstrom BC, Jardine AG, Schmieder RE et al (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360(14):1395–1407

    Article  CAS  PubMed  Google Scholar 

  88. Suzuki H, Watanabe Y, Kumagai H, Shuto H (2013) Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Ther Adv Cardiovasc Dis 7(6):306–315

    Article  CAS  PubMed  Google Scholar 

  89. FHN Trial Group, Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, Gorodetskaya I, Greene T, James S, Larive B, Lindsay RM, Mehta RL, Miller B, Ornt DB, Rajagopalan S, Rastogi A, Rocco MV, Schiller B, Sergeyeva O, Schulman G, Ting GO, Unruh ML, Star RA, Kliger AS (2010) In-center hemodialysis six times per week versus three times per week. N Engl J Med 363(24):2287–2300

  90. Matsumoto M, Io H, Furukawa M, Okumura K, Masuda A, Seto T, Takagi M, Sato M, Nagahama L, Omote K, Hisada A, Horikoshi S, Tomino Y (2012) Risk factors associated with increased left ventricular mass index in chronic kidney disease patients evaluated using echocardiography. J Nephrol 25(5):794–801

    Article  CAS  PubMed  Google Scholar 

  91. Levin A, Djurdjev O, Thompson C, Barrett B, Ethier J, Carlisle E, Barre P, Magner P, Muirhead N, Tobe S, Tam P, Wadgymar JA, Kappel J, Holland D, Pichette V, Shoker A, Soltys G, Verrelli M, Singer J (2005) Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 46(5):799–811

    Article  CAS  PubMed  Google Scholar 

  92. Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P (2009) Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. Clin J Am Soc Nephrol 4(4):755–762

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  93. Di Lullo L, Floccari F, Granata A, Malaguti M (2012) Low-dose treatment with erythropoiesis-stimulating agents and cardiovascular Geometry in chronic kidney disease: is darbepoetin-α more effective than expected? Cardiorenal Med 2:18–25

  94. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355(20):2085–2098

    Article  CAS  PubMed  Google Scholar 

  95. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, CREATE Investigators (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355(20):2071–2084

    Article  CAS  PubMed  Google Scholar 

  96. Besarab A, Goodkin DA, Nissenson AR, Normal Hematocrit Cardiac Trial Authors (2008) The normal hematocrit study: follow-up. N Engl J Med 358(4):433–434

    Article  CAS  PubMed  Google Scholar 

  97. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT Investigators (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361(21):2019–2032

    Article  PubMed  Google Scholar 

  98. Kidney Disease Outcomes Quality Initiatives (K/DOQI) (2004) Clinical practice guidelines on hypertension and hypertensive agents in chronic kidney disease. Am J Kidney Dis 43(5 Suppl 1):S1–S290

  99. Kidney Disease Outcomes Quality Initiatives (K/DOQI) (2007) Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 49(2 Suppl 2):S12–S154

  100. Kidney Disease Outcomes Quality Initiatives (K/DOQI) (2009) Clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Treatment of CKD–MBD targeted at lowering high serum phosphorus and maintaining serum calcium. Kidney Int 76(Suppl 113):S50–S69

    Google Scholar 

  101. Di Lullo L, Santoboni A, Floccari F, Rivera R, De Pascalis A, Gorini A, Barbera V, Ronco C (2014) Chronic kidney disease and sudden death. G Ital Nefrol 31(3)

  102. Herzog CA, Mangrum JM, Passman R (2008) Sudden cardiac death and dialysis patients. Semin Dial 21(4):300–307

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

All the authors have no conflict of interest to declare.

Author information

Authors and Affiliations

  1. Department of Nephrology and Dialysis, L. Parodi – Delfino Hospital, Piazza Aldo Moro, 1, 00034, Colleferro, Roma, Italy

    Luca Di Lullo, Antonio Gorini & Alberto Santoboni

  2. Division of Nephrology, University Hospital, London, ON, Canada

    Andrew House

  3. Division of Nephrology, University of Naples – Federico II, Naples, Italy

    Domenico Russo

  4. International Renal Research Institute, S. Bortolo Hospital, Vicenza, Italy

    Claudio Ronco

Authors
  1. Luca Di Lullo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew House
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antonio Gorini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alberto Santoboni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Domenico Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Claudio Ronco
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luca Di Lullo.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Di Lullo, L., House, A., Gorini, A. et al. Chronic kidney disease and cardiovascular complications. Heart Fail Rev 20, 259–272 (2015). https://doi.org/10.1007/s10741-014-9460-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-014-9460-9

Keywords

Search

Navigation